Pipeline
Investigational Medicinal Product
Disease Area of Research
Phase 1
Phase 2
Phase 3
BGB-10188 (PI3Kδ inhibitor) +/- Zanubrutinib (BTK Inhibitor)
Hematology
B-cell lymphoid malignancies
BGB-10188 +/- Tislelizumab
Hematology
B-cell malignancies
BGB-11417 (Bcl-2 inhibitor) monotherapy
Hematology
Mature B-cell malignancies
Tislelizumab (anti-PD-1)
Hematology
R/R cHL
R/R cHL
Zandelisib (PI3Kδ inhibitor) +/- Zanubrutinib or Rituximab*
Hematology
CLL/SLL and B-cell NHL
Zanubrutinib
Hematology
1L and R/R WM
R/R CLL/SLL
B-cell lymphoid malignancies
Previously treated B-cell lymphoid malignancies
R/R MZL
Zanubrutinib + Lenalidomide +/- Rituximab
Hematology
R/R DLBCL
Zanubrutinib + Obinutuzumab
Hematology
R/R FL
Zanubrutinib + Rituximab
Hematology
1L MCL
Zanubrutinib +/– Venetoclax
Hematology
1L CLL/SLL
BGB-3245 (BRAF inhibitor)
Solid Tumor
Advanced solid tumors with B-RAF mutations
Lifirafenib (RAF inhibitor) + PD-0325901 (MEK inhibitor)
Solid Tumor
Advanced solid tumors
Pamiparib (PARP 1/2 inhibitor)
Solid Tumor
2L/3L maintenance platinum-sensitive OC
1L maintenance platinum-sensitive GC
Advanced OC and TNBC
BRCA+ and HER2– BC
Pamiparib + Temozolomide
Solid Tumor
Advanced solid tumors
Tislelizumab (anti-PD-1)
Solid Tumor
1L HCC
2L advanced ESCC
2L/3L NSCLC
Previously treated advanced MSI-high or dMMR solid tumors
Previously treated unresectable HCC
Tislelizumab + BGB-10188 (PI3Kδ inhibitor)
Solid Tumor
Advanced solid tumors
Tislelizumab + BGB-15025 (HPK1 inhibitor)
Solid Tumor
Advanced solid tumors
Tislelizumab + BGB-A445 (anti-OX40)
Solid Tumor
Advanced solid tumors
Tislelizumab + Chemoradiotherapy
Solid Tumor
Localized ESCC
Tislelizumab + Chemotherapy
Solid Tumor
1L advanced ESCC
1L advanced nasopharyngeal cancer
1L advanced UBC
1L ES-SCLC
1L GC/GEJC
1L non-squamous NSCLC
1L squamous NSCLC
Resectable stage II or IIIA NSCLC
Tislelizumab + Chemotherapy / Chemoradiotherapy
Solid Tumor
Resectable ESCC
Tislelizumab + DKN-01 (anti-DKK1) + Chemotherapy
Solid Tumor
1L/2L GC/GEJC
Tislelizumab + Fruquintinib (VEGFR inhibitor)
Solid Tumor
Advanced GC/GEJC - CRC and NSCLC
Advanced GC/GEJC - CRC and NSCLC
Tislelizumab + Lenvatinib
Solid Tumor
1L HCC
Advanced solid tumors
Tislelizumab + Ociperlimab (anti-TIGIT)
Solid Tumor
1L PD-L1 high advanced NSCLC
2L PD-L1+ advanced ESCC
2L+ cervical cancer
Advanced solid tumors
Tislelizumab + Ociperlimab + BAT1706
Solid Tumor
1L HCC
Tislelizumab + Ociperlimab + Chemotherapy
Solid Tumor
1L NSCLC
Tislelizumab + Ociperlimab + Concurrent Chemoradiotherapy
Solid Tumor
Previously untreated - stage III unresectable NSCLC
Previously untreated LS-SCLC
Tislelizumab + Sitravatinib (multikinase inhibitor)
Solid Tumor
Advanced NSCLC after anti-PD-(L)1 therapy
Advanced GC/GEJC/HCC
Advanced solid tumors
Tislelizumab + Surufatinib (VEGFR, FGFR, CSF-1R inhibitor)
Solid Tumor
Advanced solid tumors
Tislelizumab + Surzebiclimab (anti-TIM-3)
Solid Tumor
Advanced solid tumors
Zanidatamab (anti-HER2 bispecific antibody)
Solid Tumor
2L+ HER2+ BTC
Zanidatamab + Chemotherapy +/- Tislelizumab
Solid Tumor
1L HER2+ BC and 1L HER2+ GC/GEJC
Australia
Australia / China
Australia / New Zealand
Australia / New Zealand / US
Australia / S. Korea / US
Australia / US
China
China / Korea
China / S. Korea / Taiwan
China / Taiwan
China / Taiwan / Thailand
Japan
S. Korea / Taiwan
S. Korea / US
Switzerland / US
Taiwan
United States
Worldwide
